Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy

  • Technology appraisal guidance
  • TA242
  • Published: 

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): consultee and commentator comments on the ACD

This page was last updated: 24 November 2011